Conjoint analysis to understand preferences of patients with multiple sclerosis for disease-modifying therapy attributes in Spain: a cross-sectional observational study
Por:
Arroyo, R, PEREZ, A, Ruiz-Beato, E, Prefasi, D, Carreno, A, Roset, M and Maurino, J
Publicada:
1 feb 2017
Categoría:
Medicine (miscellaneous)
Resumen:
Objective: To assess patients ` preferences for a range of
disease-modifying therapy (DMT) attributes in multiple sclerosis (MS).
Design: A cross-sectional observational study.
Setting: The data reported were from 17 MS units throughout Spain.
Participants: Adult patients with relapsingremitting MS.
Main outcome: A conjoint analysis was applied to assess preferences. A
total of 221 patients completed a survey with 10 hypothetical DMT
profiles developed using an orthogonal design and rating preferences
from 1 (most acceptable) to 10 (least acceptable). Medication attributes
included preventing relapse, preventing disease progression, side effect
risk, route and frequency of administration.
Results: Patients placed the greatest relative importance on the side
effect risk domain (32.9%), followed by route of administration
(26.1%), frequency of administration (22.7%), prevention of disease
progression (10.0%) and prevention of relapse (8.3%). These results
were independent of the Expanded Disability Status Scale score. The
importance assigned to side effect risk was highest for patients with a
recent diagnosis. Patients who had previously received more than one DMT
gave a higher importance to relapse rate reduction than patients
receiving their first DMT.
Conclusions: Patient DMT preferences were mainly driven by risk
minimisation, route of administration and treatment schedule. The
risk-benefit spectrum of available DMT for MS is becoming increasingly
complicated. Understanding which treatment characteristics are
meaningful to patients may help to tailor information for them and
facilitate shared decision-making in clinical practice.
Filiaciones:
Arroyo, R:
Hosp Univ Quironsalud, Dept Neurol, Madrid, Spain
:
Hosp Gen Univ Alicante, Dept Neurol, Alicante, Spain
Ruiz-Beato, E:
Roche Farma SA, Hlth Econ & Outcomes Res Unit, Madrid, Spain
Prefasi, D:
Roche Farma SA, Dept Med, Madrid, Spain
Carreno, A:
IMS Hlth, Hlth Econ & Outcomes Res, Barcelona, Spain
Roset, M:
IMS Hlth, Hlth Econ & Outcomes Res, Barcelona, Spain
Maurino, J:
Roche Farma SA, Dept Med, Madrid, Spain
Green Published, gold
|